Retro Biosciences, a biotech startup backed by OpenAI CEO Sam Altman, is underway for a Series A round of up to $1 billion to further its ambitious goal of extending human life. Previously, Altman had injected $180 million into the company for seed rounds. The company is committed to not only extending life span, but more importantly, extending healthy life span so that people can remain healthy in the last stage of their lives. This huge financing and the application of AI technology mark an unprecedented level of investment in technology and capital in the field of extending human life span.
Retro Biosciences, a biotech startup backed by OpenAI CEO Sam Altman, is conducting a $1 billion Series A round to further increase its ambition to extend human life span. Previously, Altman had invested $180 million in seed rounds into the company. Retro Biosciences’ goal is to not only extend human life span, but also extend healthy life span so that people can remain healthy at the end of their lives.
The San Francisco-based startup plans to use AI to accelerate drug development and has launched trials for drug treatments such as Alzheimer's. Retro Biosciences recently trained a model using OpenAI to convert common cells into stem cells. The company's CEO Joe Bates-La Croix said he hopes to quickly discover and develop a drug that extends human lifespan in the 2020s.
Image source notes: The image is generated by AI, and the image authorized service provider Midjourney
Retro Biosciences’ ambitions have brought it to other large-scale longevity projects backed by billionaires. These projects include Altos Labs, founded by Jeff Bezos’ $3 billion investment, and Unity Biotechnology backed by Bezos and Peter Thiel. This shows that the field of extending human lifespan is attracting more and more attention from the technology and investment circles.
Retro Biosciences not only gained capital support, but also integrated AI technology into drug research and development. Leveraging OpenAI's powerful model, the company is trying to overcome the most challenging problems in the life sciences field. The technology that converts ordinary cells into stem cells provides new hope for the future of regenerative medicine.
Altman's double investment in Retro Biosciences also reflects his recognition of the huge potential in the field of biotech. He is not only a leader in the field of AI, but is also focusing on a wider field of technological innovation. With the continuous influx of capital and technology, the extension of human life span may no longer be just a distant dream.
Retro Biosciences' successful financing and application of AI technology have injected strong impetus into research on extending human life span, and also indicates that there will be more breakthrough progress in this field in the future. Its ambitious goals and innovative technologies make people look forward to the possibility of health and longevity in the future.